Last reviewed 2026-05-15 · How we verify

Cyclonicate (CICLONICATE)

Phase 2 active Small molecule

Cyclonicate (generic name: CICLONICATE) is a ciclonicate drug. It is currently in Phase 2 development.

Cyclonicate is believed to work by interacting with specific biological pathways, although the exact mechanism is unknown.

Cyclonicate, also known as CICLONICATE, is a small molecule drug in the ciclonicate class. Its exact target and mechanism of action are unknown, but it is believed to work by interacting with specific biological pathways. The commercial status of Cyclonicate is unclear, and it is not known whether it is patented or available as a generic medication. Further research is needed to determine its approved indications, half-life, bioavailability, and key safety considerations. As a result, Cyclonicate is not yet widely used in clinical practice.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CICLONICATE
Drug class	ciclonicate
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Think of it like a key fitting into a lock. Cyclonicate is thought to be a key that fits into a specific lock in the body, allowing it to influence the way certain cells or processes work. However, the exact shape of the key and the lock, as well as how they interact, are still not fully understood.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Cyclonicate CI brief — competitive landscape report
Cyclonicate updates RSS · CI watch RSS

Frequently asked questions about Cyclonicate

What is Cyclonicate?

Cyclonicate (CICLONICATE) is a ciclonicate drug.

How does Cyclonicate work?

Cyclonicate is believed to work by interacting with specific biological pathways, although the exact mechanism is unknown.

What is the generic name of Cyclonicate?

CICLONICATE is the generic (nonproprietary) name of Cyclonicate.

What drug class is Cyclonicate in?

Cyclonicate belongs to the ciclonicate class. See all ciclonicate drugs at /class/ciclonicate.

What development phase is Cyclonicate in?

Cyclonicate is in Phase 2.

Drug class: All ciclonicate drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing